Organon & Co (OGN)
15.03
-0.28
(-1.83%)
USD |
NYSE |
Nov 15, 16:00
15.06
+0.03
(+0.20%)
After-Hours: 20:00
Organon Research and Development Expense (TTM): 473.00M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 473.00M |
| June 30, 2024 | 499.00M |
| March 31, 2024 | 511.00M |
| December 31, 2023 | 528.00M |
| September 30, 2023 | 536.00M |
| June 30, 2023 | 526.00M |
| March 31, 2023 | 504.00M |
| December 31, 2022 | 471.00M |
| Date | Value |
|---|---|
| September 30, 2022 | 439.00M |
| June 30, 2022 | 398.00M |
| March 31, 2022 | 368.00M |
| December 31, 2021 | 339.00M |
| September 30, 2021 | 289.00M |
| June 30, 2021 | 257.00M |
| March 31, 2021 | 232.00M |
| December 31, 2020 | 210.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
210.00M
Minimum
Dec 2020
536.00M
Maximum
Sep 2023
411.25M
Average
455.00M
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| ResMed Inc | 311.34M |
| TG Therapeutics Inc | 87.86M |
| Sage Therapeutics Inc | 253.20M |
| Applied Therapeutics Inc | 52.35M |